Last updated: July 18, 2026
Litigation summary and analysis for Acerta Pharma B.V. v. Cipla Limited (1:24-cv-00587)
Acerta Pharma B.V. is pursuing a patent infringement case against Cipla Limited in the US District Court for the District of Delaware (case no. 1:24-cv-00587). The dispute is a pharma IP matter filed in 2024 and tied to US market entry risk for a covered oncology product. The filing posture and claims shape Cipla’s launch timing and the scope of any US settlement or consent judgment.
What court and case details define Acerta Pharma B.V. v. Cipla Limited, 1:24-cv-00587?
Forum and docket
- Court: US District Court for the District of Delaware
- Case number: 1:24-cv-00587
- Parties: Acerta Pharma B.V. (plaintiff) vs Cipla Limited (defendant)
- Year filed: 2024
Fast read
- The case number and jurisdiction place the matter within the Delaware Hatch-Waxman venue pattern for Orange Book-related disputes.
- The 2024 filing date indicates litigation is positioned around an imminent or ongoing FDA approval and commercialization window for a competing product.
What patents and Orange Book listings are at issue in 1:24-cv-00587?
Answer based on litigation record availability
- No sufficient, citable information is available in the prompt to identify:
- the specific asserted US patents (numbers and titles),
- the Orange Book drug listing and NDA/BLA,
- the claims asserted (method-of-use vs composition vs formulation),
- the FDA submission type (ANDA vs 505(b)(2)).
Because actionable litigation analysis requires those particulars (to map expiration, enforceability posture, and infringement theory), a complete and accurate summary cannot be produced from the information provided.
What is the litigation timeline for 1:24-cv-00587?
Answer based on litigation record availability
- The prompt does not include docket events (complaint date, answer date, scheduling order, claim construction, preliminary injunction motions, or trial schedule).
- Without those docket dates, it is not possible to construct a reliable timeline.
A complete timeline is essential to gauge:
- whether the case is in pleadings, early claim construction, or dispositive motions,
- whether paragraph IV certifications or “at-risk” entry occurred,
- whether a settlement is likely to be imminent.
What infringement theories and defenses typically drive outcomes in Delaware Hatch-Waxman cases like this?
Answer based on general framework
Even without the specific patents, cases in this lane typically turn on:
- Infringement claim construction (scope of asserted product-by-process or structural limitations),
- Validity attacks such as novelty, obviousness, written description, enablement, and prosecution history estoppel,
- Indefiniteness or lack of claim certainty for certain formulation or method claims,
- Non-infringement for dosage form, excipients, salt form, polymorph, or manufacturing parameter differences.
However, applying these generally to this specific docket would risk being speculative without the asserted patent list and claim chart facts.
How does the case affect Cipla’s generic or authorized entry risk?
Market impact logic
- If Acerta’s patents cover a composition or formulation, Cipla’s entry is typically constrained by:
- design-around feasibility,
- whether any “non-infringement by process” pathway exists,
- whether the asserted patents are likely to be invalidated.
- If the patents are method-of-use related, risk shifts to label design and prescribing conditions.
But the prompt provides no Orange Book listing, NDA number, or asserted claims, so the actual launch-risk magnitude cannot be quantified.
What is the strength of Acerta’s asserted patent estate in 1:24-cv-00587?
Answer based on record availability
Patent-strength analysis requires:
- the specific asserted patent numbers,
- their priority dates, expiration dates, terminal disclaimers, and prosecution history,
- prior art relevance and claim scope,
- whether the patents are device/formulation/method claims with typical defensibility patterns.
The prompt contains no patent identifiers, so strength cannot be computed.
What settlement outcomes are plausible in 1:24-cv-00587?
Answer based on record availability
Settlement projections depend on:
- whether there is an exclusivity trigger,
- proximity to patent expiration,
- whether Cipla filed a Paragraph IV certification,
- whether the patents include system-of-use or composition protections.
No docket or agreement details are provided, so no accurate settlement analysis is possible.
What is the procedural posture for claim construction, injunction, or trial?
Answer based on record availability
The prompt provides no:
- hearing dates,
- Markman schedule,
- discovery deadlines,
- motions for preliminary injunction or summary judgment,
- trial date.
Without docket facts, a procedural posture summary would be incomplete.
What does the case mean for regulatory pathways and FDA exclusivity?
Answer based on record availability
To analyze regulatory implications, the following are required:
- the FDA NDA/BLA tied to the Orange Book,
- the approval date and exclusivity (5-year/7-year data exclusivity; patent exclusivity under 35 USC 156),
- whether Cipla’s ANDA includes one or more Paragraph IV certifications,
- whether any shared-label or carve-out strategy is used.
None of these are provided, so the FDA analysis cannot be made.
Which companies are most exposed and how does Acerta’s litigation compare with similar oncology disputes?
Answer based on record availability
This requires cross-referencing:
- comparable suits by other brand holders against Cipla or other generics,
- whether the same molecule is involved,
- whether the same patent family is asserted.
The prompt includes no molecule or asserted patents, so comparison is not possible.
Key Takeaways
- Case identity: Acerta Pharma B.V. vs Cipla Limited, 1:24-cv-00587 in D. Delaware (filed in 2024).
- Action needed for full IP analysis: specific asserted patents, Orange Book listing, and docket events are required to produce a complete infringement-validity-timeline-and-launch-risk assessment.
- No further reliable case specifics are available in the prompt to support an accurate patent-by-patent or procedural posture summary.
FAQs
- What is the typical role of paragraph IV certifications in Delaware cases involving Acerta Pharma and generic applicants?
- How do method-of-use versus composition claims change non-infringement design-around strategy?
- What factors drive whether a Hatch-Waxman case settles before Markman in the District of Delaware?
- How do patent expiration dates and any pediatric exclusivity alter FDA launch timing in US oncology disputes?
- What discovery items most influence validity challenges (prior art databases, prosecution history, expert claim charts) in pharmaceutical litigations?
References
- (Not provided in the prompt: no citable court docket entries, patent numbers, or FDA Orange Book listing details.)
